Art is a powerful tool for connection, transformation, and expression. And when it is combined with science, it can become an inspiring symbol of hope and progress. That's what happens with the trophy of Renata Thormann Procianoy Award, created by the visual artist Fernanda Frangetto, which gave shape to a symbol of recognition and celebration of the dedication of doctors and scientists to the cure of cancer.
Fernanda has a trajectory marked by multiple languages and the search for profound meanings, which connect the individual to the collective. Her story of overcoming and her sensitive eye for social and scientific causes made her the ideal artist to create the trophy that, since 2019, has accompanied the legacy of the Healing Project.
“My art is a path to self-knowledge and inner healing.”
Fernanda Frangetto
1. How do you define yourself as an artist and how has your trajectory so far influenced the type of art you produce today?
I'm a mixed-media visual artist. I explore various techniques and materials. From organic materials, such as beeswax, to industrialized materials such as metal and acrylic. I use various forms of art: sculpture, installation, painting and drawing.
I won my first prize at the age of seven when I was entered in a painting contest held by Ultrafértil S/A, a factory designed by the American company Phillips Petroleum Co., where my father, a chemical engineer, worked.
I can say that science was also able to advance my career, because at that time I had a genetic condition, where my nails became more fragile. So I was able to make works with the use of brushes instead of finger painting on medical advice, and I was able to develop my skills with greater precision.
As a teenager I took an academic painting course. I began my career of studying sculpture in depth during a time of searching, after suffering a car accident, experienced at the age of 15. For a vain young woman, an exposed scar on her right arm popped through her eyes, and the driver's splenectomy was traumatic. Thanks to my mother's good recommendation, I was able to be taught by teachers, Giuliana Pedrazza and Carlos Alberto Garcia Arias, who helped me to re-establish self-esteem and art itself did the rest.
In these 34 years of artistic trajectory, the aesthetic and symbolic forms of my creations have greater meaning as the openness and intimacy of the observer's collective unconscious contact with the more subtle and contemplative forms. This is mainly due to the meditative vein that, for example, the sacred drawings in the current series suggest.
2. The Renata Thormann Procianoy Prize trophy was created in 2019 for the first edition of the award. How was the invitation and what did it mean for you to develop a piece for recognition linked to science and care for life?
I am honored to have received the invitation to develop and execute the design of the Renata Thormann Procianoy Prize trophy.
It is important for me to create an affinity with the theme of the proposal of artistic projects, whether related to education, the environment, the social sector, or religion so that I can achieve something unique. It's not enough just to be something solid: I like to know deeply, to talk to the idealist of the proposed project until I find the vein that unites us.
Fernanda Schwyter, CEO of the Cura Project Institute, was present at Brazil Fashion Miami 2017 and learned about the trophy I had won for the event at the Faena Forum Cultural Center Miami Beach. Then, we worked together to support student programs at an annual philanthropic event, Gala - Gulliver Prep, in South Florida.
Also in 2017, I was the artist invited by the American Cancer Society to create a limited edition of the trophy to honor the Relay For Life event, in collaboration with the city of Doral, in South Florida, and the Commissioner's Office of Miami-Dade County, in the United States.
The invitation to create the design for the Renata Thormann Procianoy Prize came directly from Fernanda Schwyter. I was moved by the story of the Procianoy family and Renata T. P.'s dedication to finding a cure for her mother, Nora Thormann Procianoy. My namesake and I have an affinity in the search for faith that unites us and helps us to foster the ideals of the Healing Project.
The Scientific Prize, with the multidisciplinary support of professionals, is of exceptional value, much more than a simple prize, in its entirety of the global need for research to cure cancer.
3. Tell me a bit about the concept of trophy art: what did you want to convey with art? What forms and elements did you choose and why?
The final representation of the two layers of acrylic print is minimalist. The upper front part bears the inscription Project Cura in the original colors and its description.
Below, the award title in black ink pigment, where the colored Cura logo is the central highlight, demonstrated in the circles in the background with the artist's signature on the lower right of the rectangular acrylic plate. It supports itself when supported on any flat surface.
A discreetly scaled frame and chromosome-shaped tones encircles the four ends of the pictorial field printed in the foreground. This organic form serves as a symbol, in harmony with research for the discovery of a cure for cancer, between a palette dialogue corresponding to cell mutations and inheritances transmitted by DNA, in alliance, like hand in hand, in repetitions of sections juxtaposed under acrylic.
4. How was the process of creating and producing the piece?
The inspiration came from the CURA logo itself and the meaning of the Cura Project.
Initially, the process was developed in digital collage, graphic design and acrylic printing plans. Each piece undergoes chromatic adjustments of print data on the acrylic and aluminum plate, personalized with the name of the doctor, the awarded scientist.
5. The Prize is now reaching its 7th edition and the trophy remains a strong symbol of that recognition. How do you feel to see your art perpetuating that legacy?
Being part of the legacy of the Prize with my artistic participation to honor medical doctors since its first edition transcends art itself and my achievement as an artist. Just as art can also be a path to inner healing, the Healing Project creates the ideal condition and union to stimulate scientific research.
We are very grateful to the artist Fernanda Frangetto for sharing his story, his creative process and for having transformed the purpose of the Cura Project Institute into such a symbolic and significant piece. The trophy of Renata Thormann Procianoy Award carries a deep sense of connection between art, science, care and humanity.
We congratulate Fernanda for her inspiring trajectory and for continuing to create works that touch, connect, and perpetuate such noble causes. May your art continue to be a path of transformation and hope for all who encounter it.
The ASCO, the largest oncology congress in the world, took place in Chicago from May 30 to June 03 of this year, and the CURA Project Institute was present, through the presentation of the work “Oncology patients' view of clinical research in Brazil: concerns, knowledge and prejudices - a national survey” in which results were demonstrated on the interview conducted with about 300 cancer patients, including clinical research participants. This survey was conducted by the Oncologist and President of the Scientific Committee of the Cura Project Institute, Dr. Heloisa Resende, in partnership between Cura and LACOG.
Here we share a vision about studies that we believe will bring great benefits to our patients:
CHALLENGE Study
Presented by Dr. Christhopher Booth, who evaluated the impact of physical activity on patients who underwent chemotherapy after surgical and chemotherapy treatment for colon cancer, it was one of the most applauded at ASCO.
In this study, patients were randomized (randomly separated into 2 groups), in which one group received a well-structured physical activity program by specialized professionals and the other group was observed.
At the end of the follow-up period, a significant reduction in the risk of death was demonstrated for the group that received the physical exercise program, this gain being greater even than some chemotherapy regimens
This study has already been published in the journal NEJM, on June 1, 2025, one of the most prestigious journals in the world.
The need for each of us health professionals to encourage the practice of physical activity and the mission of patients to think about and adhere to the proposal, which is proven year after year, as a valuable strategy in the fight against cancer, is demonstrated.
Care and quality of life: study shows safety in the use of estrogen-containing vaginal creams in breast cancer survivors
During the session dedicated to survivor care, an important breakthrough was presented: researchers demonstrated that vaginal creams with low estrogen concentrations can be used safely by patients who have already undergone breast cancer treatment, including those with hormonal tumors, that is, with positive hormone receptors.
This strategy represents a new possibility of care that can make a significant difference in the quality of life of these women, alleviating common adverse effects related to cancer treatment that affect patients' well-being and intimate health.
Advances in the treatment of Metastatic Breast Cancer
The treatment of metastatic breast cancer has undergone important transformations, with promising results that directly impact patients' quality of life and survival. Two major innovations have redefined the therapeutic standard for different subtypes of the disease:
Novelty for patients with positive hormone receptors and HER2 negative
For patients with hormone receptor-positive and HER2-negative metastatic breast cancer, the new standard becomes a combination with three medications: cyclin inhibitor, inavolisib, and fulvestrant.
This change is based on the results of the study INAVO120, which demonstrated a significant increase in survival among patients who received this combination therapy.
New approach for HER2-positive patients
Another important change, which had already been expected, concerns HER2-positive metastatic breast cancer. The Study Destiny-Breast09 (DB-09) revealed that the combination of Trastuzumab Deruxtecan (TDXD) With pertuzumab is more effective at controlling the disease than the previous regimen, which included trastuzumab, pertuzumab, and chemotherapy.
In addition to greater efficacy, this new combination has the great benefit of delaying chemotherapy for this group of patients.
GBECAM initiative focuses on caring for cancer survivors
And we couldn't fail to mention a very important initiative of the Oncoclinics group, led by Dr. Luciana Landeiro, president of GBECAM and one of the winners of previous editions, of the Renata Thormann Procianoy award, and Dr. Thaiana Santana, of the GBECAM Patient Support Committee.
The researchers presented a study that implements individualized care strategies for cancer survivors, especially in the post-chemotherapy phase. The focus is on physical and emotional support, with management of the possible sequelae left by the treatment.
This successful initiative needs to be replicated elsewhere in the country. To this end, it will be essential to build collaborative strategies between medical researchers from different parts of Brazil. Through cooperation between research groups, it is possible to transform knowledge into action and, more importantly, to bring this care to an increasing number of patients, proposed by the largest oncology congress in the world in 2025.
The CURA Project Institute has supported researchers, helping to raise funds and promote patient awareness campaigns to make this mission of transforming knowledge into action increasingly possible.
Text and collaboration: Dr. Heloisa Resende — Oncologist, Researcher and President of the Scientific Committee of the Cura Project Institute
Law No. 14.874/2024 represents an important milestone for the regulation of clinical research in Brazil, bringing significant advances and changes, especially with regard to the continuity of treatment with experimental drugs after the end of clinical trials.
To clarify and update this topic of great relevance to patients, health professionals, researchers and sponsors, the Cura Project Institute, with the collaboration of the lawyer specializing in the Right to Health, Jéssica Leda, presents a detailed analysis of the main points of the new legislation.
Follow the full content and understand how the new Law impacts the guarantee of access to experimental treatments, the legal criteria for their continuity or interruption, and the fundamental role of the Research Ethics Committees in this process.
Law No. 14.874/2024 establishes new guidelines for clinical research with human beings in Brazil, including specific provisions on the supply of experimental drugs after the end of studies.
Until the enactment of the new Law, Resolution No. 466/2012 of the National Health Council (CNS), the sponsor of the study was required to guarantee, for an indefinite period, free access “to the best prophylactic, diagnostic and therapeutic methods that proved to be effective”. With the new Law, however, this obligation may be interrupted under certain circumstances, subject to justification submitted to the evaluation of the Research Ethics Committee (CEP).
Post-Study Access Plan
Before the start of the clinical trial, sponsors and researchers must submit a post-study access plan to the CEP, justifying the need - or not - of continuing the free supply of the experimental drug after the end of the research, for participants who may need continued treatment.
Criteria for continuity of supply
According to the Law, free provision must be maintained whenever treatment is considered the best therapeutic option for the participant and when it presents a more favorable risk-benefit ratio compared to other available treatments. In addition, the decision must take into account aspects such as:
In these cases, the responsibility for the supply lies with the sponsor.
Hypotheses of supply interruption
The Law also defines situations in which the free supply may be interrupted, provided that there is justification and approval by the CEP, based on the criteria provided for in the Law itself, among which the following stand out:
Presidential Veto of Article 33, Item VI
During the presidential sanction of Law No. 14.874/2024, item VI of article 33 was vetoed, which provided for the possibility of interrupting the free supply of the drug 5 (five years) after its commercial availability in Brazil. The justification for the presidential veto was that such a provision could compromise the rights of the participants and the conduct of ethical research, in disagreement with the principles of dignity, beneficence, and justice.
Despite the veto, Article 33 maintained other hypotheses of supply interruption, especially item VII, which authorizes the termination of the obligation when the experimental drug is incorporated into the SUS - Unified Health System.
Evaluation by CEP
In all cases, the interruption of the free provision is conditioned on the evaluation and approval of the Research Ethics Committee, as well as compliance with the criteria established by the Law.
At the Cura Project Institute, we continue to follow closely the changes in the regulatory landscape, always with the commitment to informing and strengthening the dialogue between society, health professionals, researchers and the public authorities.
O Instituto Projeto Cura é uma instituição de vanguarda e a precursora nos assuntos de pesquisa clínica no Brasil. Sem fins lucrativos, foi criado em 2016 com a missão de conscientizar a sociedade sobre os benefícios das pesquisas clínicas e sua importância para os avanços no tratamento do câncer, um tema essencial para a saúde pública e a qualidade de vida da população do Brasil e demais países da América Latina.
Em mais uma iniciativa de conscientização sobre as Pesquisas Clínicas, no dia 28 de março, durante o Cura Talks GBECAM, o Instituto Projeto Cura apresentou a primeira etapa da Campanha Caminhando com Confiança: entendendo as Pesquisas Clínicas, que tem como objetivo ampliar o conhecimento sobre a importância das pesquisas clínicas. A campanha foi estruturada com a curadoria de médicos oncologistas e pesquisadores, trazendo informações em uma linguagem simplificada e de fácil compreensão.
%2015.02.57_4c2bec24.jpg)
Campanha Caminhando com Confiança: entendendo as Pesquisas Clínicas
Você sabia que os tratamentos que temos hoje só existem graças à pesquisa clínica? Estudos clínicos são essenciais para desenvolver novos medicamentos e terapias que podem transformar a saúde de milhões de pessoas.
Participar de uma pesquisa clínica é seguro, voluntário e pode proporcionar acesso a tratamentos inovadores. Além disso, o paciente contribui para o avanço da ciência e ajuda a salvar vidas.
A Campanha Caminhando com Confiança: entendendo as Pesquisas Clínicas idealizada pelo Instituto Projeto Cura, busca informar, de forma simples e acessível, como funcionam as pesquisas clínicas e a importância da participação ativa dos pacientes.
As pesquisas clínicas são fundamentais para o avanço da ciência e para o desenvolvimento de novas terapias contra o câncer. No entanto, muitas dúvidas ainda cercam esse tema. Para esclarecer questões e democratizar o acesso à informação, a Campanha Pesquisas Clínicas está sendo realizada por meio de duas frentes principais:
1. Mídia impressa:
● Distribuição de folders informativos em hospitais, centros médicos e institutos de pesquisa, levando conhecimento acessível e confiável para profissionais da saúde, pacientes e o público interessado.
2. Mídia digital:
● Publicação de conteúdos educativos nas plataformas do Instituto Projeto Cura, abordando os conceitos fundamentais das pesquisas clínicas, seu impacto na saúde e o papel da sociedade nesse processo.
● Vídeo "Caminhando com Confiança: entendendo a pesquisa clínica", disponível no canal do YouTube do Instituto Projeto Cura. Confira aqui:
Essa é mais uma das campanhas idealizadas pelo Instituto Projeto Cura ao longo de sua trajetória. Além dessas iniciativas de conscientização, o Instituto realiza eventos especializados, focados em levar informações relevantes para pacientes, redes de apoio, profissionais da saúde e ONGs da área da oncologia. Também promove eventos técnicos voltados para políticas públicas, fortalecendo o debate sobre a importância das pesquisas clínicas no Brasil.
%2015.00.33_3a0f0097.jpg)
O Instituto Projeto Cura expressa seu agradecimento à Daiichi, cujo apoio torna possível a realização desta campanha, ampliando o alcance da informação e contribuindo para um maior entendimento sobre pesquisas clínicas e sua relevância no cenário oncológico.
Os conteúdos da campanha estão sendo divulgados nas Redes Sociais do Instituto Projeto Cura e convida a todos a se engajarem nessa iniciativa. A conscientização sobre as pesquisas clínicas é essencial para que cada vez mais pacientes possam ter acesso a tratamentos inovadores e esperança de melhores resultados no combate ao câncer.
Acompanhe os conteúdos no nosso Instagram:
https://www.instagram.com/p/DGlJw1CJ6qv/
https://www.instagram.com/p/DF56k2yqAQe/
https://www.instagram.com/p/DGgi09TyTSX/
On March 28, 2025, the Grand Hyatt São Paulo hosted the edition of Cura Talks GBECAM, an event that brought together specialists, patients, and health professionals to discuss advances in the fight against breast cancer. Part of the official programming of Brazilian Breast Cancer Conference, carried out by LACOG and GBECAM, the meeting provided a full day of exchange of experiences, scientific knowledge, and debates on fundamental topics for confronting the disease. An audience of more than 100 people attended the event, which lasted 9 hours and has already surpassed 350 views, in the recording available on the Cura YouTube Channel.
The event began with a welcome coffee, followed by the opening led by the President of the Cura Project Institute, Fernanda Schwyter and by the President of Gbecam — Brazilian Breast Cancer Studies Group, Dr. Luciana Landeiro, who welcomed the participants and reinforced the importance of the meeting for the dissemination of information about clinical research in breast cancer.
The first panel of the day, “Getting to Know Breast Cancer: Subtypes and Treatments”, was attended by doctors Dr. Max Mano and Dr. Otto Metzger, under the moderation of Dr. Jose Márcio Figueiredo, providing an in-depth view of the different types of breast cancer and the most current therapeutic approaches. Dr. Max Mano, in his approach, brought us a fact that has been worrying for many years:
“Two-thirds of patients in the public system are no longer diagnosed with the disease starting or with armpit ganglia, or already metastatic, and this is double the world average.”
Next, the debate “Patient Journey and Clinical Research”, moderated by Dr. Gilberto Amorim, brought shocking accounts from the Brazilian patient, who lives in the United States, Julia Maués, accompanied by the doctors Dr. Lilian Arruda and Dr. Heloisa Resende, evidencing the importance of including patients in clinical studies and the impact of these researches on quality of life. Regarding Clinical Research, we have the report of the patient with metastatic breast cancer, Julia Maués:
“I had very difficult health moments and finally there came a time when a medicine started to work, and this only happened because years before, decades before, people participated in research to make this medicine exist. Without these patients who participated in these studies, I would not be here and without the health professionals who dedicated themselves to research and did these studies, I would not be here. So even people who don't participate in research are only here because of research.”
Os Highlights of the ASCO & SABCS 2024 conferences, presented by the experts, Dr. Jose Bines, Dr. Heloisa Resende, Dr. Abna Vieira and Dr. Pedro Freire and moderated by Fernanda Schwyter, provided an overview of the main scientific advances discussed at the most important international conferences on breast cancer. According to Dr. Heloisa Resende, who provided a qualitative vision of SABCS 2024:
“There is a total tendency to individualize treatments, so we are on the one hand about scaling up, this is a strong aspect, and we have seen several studies in this regard. An attempt by the scientific community to relieve the system and improve the patient's quality of life. If we think that it is a context of metastatic disease, quality of life becomes the main hand pointing”.
A special moment was reserved during Cura Talks Gbecam, where the Clinical Research Campaign, an initiative of Cura Project Institute, sponsored by Daiichi, which aims to promote knowledge about the importance of clinical research in oncology, through the structuring of an information campaign, which was curated by oncologists and researchers in a simplified and easy-to-interpret language.
Check out the video for the “Walking with Confidence: Understanding Clinical Research” Campaign:
In the afternoon, one of the expected moments was the round table “How do innovations reach our patients?”, conducted by Dr. Nelson Teich and Marlene Oliveira, moderated by Catia Duarte, highlighting challenges and opportunities in accessing new technologies and treatments. Dr. Nelson Teich brought us some data regarding per Capta expenditure on health, in Brazil and in the world:
“Brazil has little relevance in global health, in terms of expenditure (per person on health). This is important for people who carry out global research because they are not 200 million people, but Brazil only represents 1.6% of world spending, and America, which is the flagship, represents 41%”.
The challenges faced by patients after cancer treatment were the subject of the panels “Life After Cancer”, who addressed aspects such as sexuality, physical activity and return to work. For the first issue, the event was attended by Oncologists Dr. Andreza Souto, Dr. Thaiana Aragão and patient Ana Cristina Reis, moderated by Dr. Maria Cristina Figueroa, and the second part of the module was attended by Dr. Gabriela Prior, Ângela Castro and Influencer and Patient Gi Charaba, moderated by Catia Duarte, bringing medical and personal perspectives on these essential topics for rehabilitation.
To start the first module, Dr. Maria Cristina left an important message: “Thank you for the opportunity to be here, with whom you move everything we do every day, because you are the patients. It is an invitation for us to join forces so that you are more and more understood about the subject, so that every fight that we face, we are together. They are people who need to know their rights and duties every day.”
According to the Moderator of the Return to Work Module, Catia Duarte: “Professional life is very important, and cancer cannot define how far each patient's career can go” and it is on this subject, in how companies are preparing or are prepared to receive this patient that the CEO of Araetá Strategy tells us that “We are unable to identify any company (consulted) that today has a program aimed at this topic. It's not on the agenda, or it has a series of actions in October, but it's not a care”.
The closing included a interactive debate About relationship between doctors, patients and support network, bringing together the experts Dr. Ana Coradazzi, Dr. Roberto Hegg, the patient Eny Estevam Rodrigues and support network representative, Catia Duarte, with the mediation of Fernanda Schwyter. The panel provided an enriching exchange about the role of each individual in confronting breast cancer and in building a more humanized treatment. According to Dr. Ana Coradazzi, within oncology, doctors have the opportunity to build this relationship with the patient:
“What struck me were the times when I couldn't help because I couldn't establish the relationship I would like. And I think that makes the difference in the doctors' relationship with their patients, you don't have to be your patient's best friend, you need to be close enough to understand what they need from you, and the minimum is that you understand their context, their reality, then you look at the data you have at your disposal, you look at the resources that you have at your disposal, which are not always what the literature shows and then you create with it a care strategy that makes sense and is aligned with what he needs. That is the relationship between doctor, patient, family and team, it is a building”.
Acknowledgements
Cura Talks GBECAM 2025 was a success! We thank all the participants, speakers, and mediators who shared knowledge and contributed to strengthening clinical research as an essential tool in the fight against breast cancer.
Special thanks to LACOG and GBECAM for their fundamental partnership in holding this event, and to Daiichi Sankyo, whose support was essential for this journey of innovation and patient care.
If you were unable to follow the event or wish to review the content presented, the full broadcast is available on the Instituto Proyecto Cura YouTube channel: Watch it here.
Photo credit: Casa da Photo
Law No. 14,758/2023, which establishes the National Cancer Prevention and Control Policy (PNPCC) in the Unified Health System (SUS), came into force in June 2024. Its main objective is to reduce the incidence of cancer and ensure full access to treatment for patients.
For the PNPCC to be effectively implemented, urgent regulation was necessary, especially in fundamental aspects such as financial incentives, integration between the Federal Government, states and municipalities, definition of goals, and training of health professionals. After seven months of waiting, the Ministry of Health published three ordinances (Ordinances GM/MS No. 6,590, 6,591, and 6,592) that regulate the policy. These regulations create the Cancer Prevention and Control Network and establish the Navigation Program for People Diagnosed with Cancer in the SUS.
The measures were agreed by the Tripartite Interagency Committee (CIT), in partnership with the Ministry of Health, the National Council of Health Secretaries (Conass) and the National Council of Municipal Health Secretaries (Conasems). Among the most important advances, the following stand out:
• Expansion of telehealth to support remote diagnosis and treatment;
• Agreement between the Federal Government, states and municipalities for shared accountability;
• Strengthening Primary Health Care (PHC) in the regulation of care;
• Incorporation of palliative care at all levels of care;
• Guarantee of cancer diagnosis within legal time limits;
• Training of teams for screening, diagnosis, and effective treatment;
• Reduction of unnecessary travel and greater adherence to treatment.
• Challenges and gaps in regulation
Despite the progress represented by the ordinances, uncertainties still persist about the effectiveness of the implementation of the PNPCC in practice. The regulations address some issues excessively broadly, without detailing concrete mechanisms for their application, in addition to the absence of clear definitions, such as federal funding to reduce regional disparities in access to services, a fundamental aspect to guarantee the viability of the planned actions. Without these clarifications, the implementation of the policy may face operational obstacles and compromise equitable access to cancer treatment in the SUS.
“In addition, a fourth ordinance, still under discussion, will address the purchase of oncological drugs. This text will define the rules for access to medicines and will establish the component of pharmaceutical care in oncology in the SUS.
Given this scenario, there are still doubts as to whether the regulations will be sufficient to guarantee effective cancer care in the SUS. The PNPCC will depend not only on established guidelines, but also on efficient execution, with adequate funding, coordination between federal entities, and continuous monitoring so that advances translate into real benefits for patients.”
Collaboration: Dr. Jéssica Léda - Lawyer
The Cura Project Institute is pleased to announce the Cura Talks GBECAM — Symposium for Patients, which will be held on March 28, 2025, from 8:30 to 18:00 at the Grand Hyatt Hotel, in São Paulo/SP. The event is part of the Multidisciplinary Symposium program, part of the renowned LACOG-GBECAM Breast Cancer Conference.
Dedicated to patients, support networks, representatives of patient organizations, health professionals, journalists and influencers, Cura Talks GBECAM is a unique opportunity to update on clinical studies and research, in addition to sharing the most recent advances in the treatment and care of breast cancer and that have changed in current behavior. The event aims to promote a space for open dialogue and knowledge exchange, in a language accessible to the public, addressing scientific advances with a focus on clinical research and the direct impact on patients.
The symposium will be attended by renowned experts in the field, who will share their experiences and innovations. The interactive format will allow participants to talk directly with the speakers, making the meeting dynamic and enriching.
In-person registrations for Cura Talks GBECAM are free and must be made through the link: https://www.sympla.com.br/evento/cura-talks-gbecam-simposio-para-pacientes/2799877
Check the schedule (*subject to adjustment):
08:30/08:50 - WELCOME COFFEE
08:50/09:00 - OPENING
09:00/09:30 - KNOWING BREAST CANCER: Subtypes and treatments
09:30/10:00 - PAPO CURA
10:00/10:40 - PATIENT JOURNEY AND CLINICAL RESEARCH
10:40/11:00 - PAPO CURA
11:00/11:30 - BREAK
11:30/12:15 - HIGHLIGHTS ASCO & SABCS 2024
12:15/13:00 - PAPO CURA
13:00/14:00 - LUNCH
14:00/14:30 - HOW DO INNOVATIONS REACH OUR PATIENTS?
14:30/15:00 - PAPO CURA
15:00/15:30 - LIFE AFTER CANCER: SEXUALITY + YOUNG PATIENTS AND BREAST CANCER
15:30/16:00 - LIFE AFTER CANCER: RETURN TO WORK, HOW COMPANIES APPROACH THIS PROCESS
16:00/16:30 - PAPO CURA
16:30/17:00 - BREAK
17:00/17:50 - INTERACTIVE DEBATE: Doctor-Patient Relationship — Support Network
17:50/18:00 - CLOSING
The Cura Project Institute is an essential part of the discussions about cancer in Brazil, standing out as a cutting-edge institution in clinical research. Committed to creating opportunities for dialogue and continuous learning, Cura seeks to improve care and raise the quality of life of cancer patients.
GBECAM — Brazilian Breast Cancer Studies Group is a partner of the Cura Project Institute at this event, reinforcing the joint mission of promoting advances in research, education, and awareness about breast cancer.
Take part in Cura Talks GBECAM and contribute to a healthier and more informed future. Reserve your spot and be part of this essential conversation for the fight against breast cancer.
Follow us on Social Networks to have access to all the information about the event:
Instagram - https://www.instagram.com/projetocura/
Facebook - https://www.facebook.com/projetocura.org
LinkedIn - https://www.linkedin.com/company/projetocura
O Talks Breast Care, an event organized by the CURA Project Institute, was highlighted on Drauzio Varella's important medical portal for addressing racial inequality in the context of breast cancer. Gramado (RS) was the scene of an essential debate about the challenges faced by black women in accessing the diagnosis and treatment of the disease, in addition to the need for greater racial representation in clinical oncology research.
Alarming data reinforce the urgency of the topic: although more than half of the Brazilian population is black (black and brown), only 24% of women who undergo mammography exams belong to this group. On the other hand, black women represent 47% of serious cases of breast cancer, according to a study conducted by the Avon Institute in partnership with the Oncology Observatory, based on data from DATASUS between 2015 and 2021.
According to Portal, another study, published in the journal Breast Cancer Research and Treatment, revealed that black women in Brazil are diagnosed at more advanced stages of the disease and have three times higher mortality rates compared to white women. In the United States, breast cancer mortality is 40% higher among black women, showing that racial inequality is a global phenomenon.
During Cura Talks Breast, Dr. Ana Amélia Viana, clinical oncologist and coordinator of the Diversity Committee of the Brazilian Society of Clinical Oncology (SBOC), emphasized that access barriers and lack of representation in clinical research significantly hinder the journey of black women seeking early diagnosis and appropriate treatment. “To change this scenario, it is essential that clinical research be more inclusive and reflect the diversity of the Brazilian population,” he said.
Check out the content on the Drauzio Varella Portal by clicking on the link: https://drauziovarella.uol.com.br/oncologia/cancer-de-mama-mulheres-negras-enfrentam-desigualdades-no-diagnostico-e-tratamento-da-doenca/
Dr. Carlos Barrios, an oncologist, director of the Latin American Oncology Clinical Research Group (LACOG) and researcher at the Oncoclinics Group and São Lucas Hospital of PUC-RS, also participated in the Cura Talks Breast Gramado, making fundamental contributions in the field of clinical research. Dr. Barrios is a mentor and constant presence at the events of the CURA Project Institute, collaborating for significant advances in the area of Oncology and made his contribution on the subject:
The evolution of the human being in social interactions has provided formidable advances in several areas. Innovative technologies, which allow better disease control, development of new drugs and increased food production, have contributed to a significant increase in life expectancy and quality of life. We live longer and better, reflecting collective efforts in science, technology, and global cooperation.
However, it is impossible to ignore that the benefits of these advances are not evenly distributed. Discrepancies in access to and availability of essential resources represent a universal challenge and result in marked inequalities between different countries and, often, even between regions of the same country. Ethnic and racial minorities, and stigmatized social groups are often left on the sidelines, being deprived of full participation in advances that should benefit everyone.
This scenario not only affects minorities, but also large portions of the world's population that live outside of privileged regions, where access to cutting-edge technologies and basic care is still a distant luxury. Thus, inequity, more than a specific problem, has become a structural feature that defines our global society.
Recognizing this reality is the first step in seeking change. However, it is essential to avoid simplifications. Inequalities have multiple dimensions, and to propose definitive diagnoses or unique solutions would be naive. The approach must be individualized and contextualized. Each of us can identify the inequities around us and act locally, seeking to solve small challenges that, together, have the potential to create significant transformations.
In the area of clinical research, particularly in the field of oncology in Brazil, there is a growing effort to include historically underserved populations. The medical community, through initiatives such as the Cura Project and LACOG, works with a clear purpose: to design and conduct studies that address crucial issues for everyone, especially for minorities and marginalized populations. The commitment goes beyond generating knowledge; it is creating transformative solutions that impact lives in a broad and inclusive way.
This task, however, is complex and cannot be performed in isolation. It requires the active collaboration of various segments of society. Building a culture of cooperation, where each individual, institution, and sector contributes according to their capacity, is essential. Only by joining efforts will we be able to move towards a more just and egalitarian world.
The Cura Project and LACOG are concrete examples of this vision. These platforms provide opportunities for the active participation of all stakeholders, promoting inclusion and mobilization around a common goal: reducing health inequalities and ensuring that advances in science truly benefit everyone. Supporting these initiatives is investing in building a more equitable society, driven by the dream, dedication, and leadership of committed volunteers.
Working together, with solidarity and purpose, is the path to achieving a more just and promising future for all humanity.
.jpeg)
Dr. Heloisa Resende, president of the Scientific Committee of the CURA Project Institute, reinforced the organization's commitment to promote clinical research that provides answers relevant to oncology. “The CURA Institute works in three main areas: education and awareness for the lay public about the benefits of research and the rights of participants; debates with opinion leaders to identify obstacles to clinical research; and fundraising for academic projects.”
An example is the Impact of Extreme Social Vulnerability & Breast Cancer Study: a population-based study in Brazil, led by Dr. Max Mano and supported by the CURA Project Institute. This project aims to analyze the impact of social factors on breast cancer treatment outcomes in Brazil, helping doctors to better understand the particularities of their patients and their social contexts.
Racial inequality in breast cancer is a reflection of the historical barriers faced by the black population in Brazil, which include lower access to health, late diagnoses, and less effective treatments. Cura Talks Breast proved to be an essential event to promote discussions about solutions that can change this scenario, in addition to reinforcing the importance of including black women in clinical studies.
By bringing together experts and fostering constructive debates, the CURA Project Institute reaffirms its commitment to reducing inequalities and building a more just and egalitarian future for all women.
Dr. Carlos Barrios, who is a constant presence at the Cura Project Institute events, where he acts as a Mentor on essential topics in the field of clinical research, contributing to significant advances in the area of Oncology, was recognized in the 2024 edition of the annual Highly Cited Researchers survey, published by the academic consultancy Clarivate Analytics.
Acting as an Oncologist, Director of the Latin American Oncology Clinical Research Group (LACOG) and Researcher of the Oncoclinics Group and São Lucas Hospital of PUC-RS, Dr. Carlos Barrios receives credit for this prestigious ranking that highlights international scholars considered to be among the most influential in the world.
The Cura Project Institute believes that clinical research is fundamental to transform science into concrete solutions that directly impact people's lives. Guided by a mission aimed at fostering clinical research and commitment to society, Cura works to promote significant advances in the area of health, especially in the field of oncology.
This commitment is reflected in the partnership with renowned professionals, such as Dr. Carlos Barrios, and recognition such as the survey Highly Cited Researchers 2024, is proof that dedication and scientific rigor generate impacts that transcend geographical barriers, benefiting patients and health professionals on a global scale.
The Institute sees clinical research as a tool for developing new treatments and also as a means of giving voice to civil society. Through advocacy initiatives, Cura seeks to expand access to information, strengthen the relationship between researchers, patients, and governments, and encourage public policies that prioritize science and health.
The phrase “Research saves lives” encapsulates the essence of the work of the Cura Project Institute. For this reason, Cura will continue to invest in initiatives that promote research, bringing together health professionals, scientific communities and society in general.
The Cura Project Institute, with great pride and admiration, congratulates Dr. Carlos Barrios for this recognition and reinforces the importance of clinical research for the development of new treatments and the increase of patients' quality of life.
.jpeg)
.jpeg)
.jpeg)
See the list of Researchers: https://clarivate.com/highly-cited-researchers/
Meeting promoted discussions about the role of the public and private sectors in the advancement of clinical research and is now available on YouTube
On November 8, the Cura Project Institute held the 5th edition of Cura Meetings, which took place during the 25th Brazilian Congress of Clinical Oncology (SBOC), in Rio de Janeiro. The event brought together doctors, health professionals, representatives of the pharmaceutical industry and the government to discuss the topic “Financing clinical research: a coalition of medical and civil society, government and pharmaceutical industry for clinical research.”
The session was a milestone to discuss the need for joint investment and addressed how the joining of efforts between public and private sectors can promote the development of new treatments for cancer. The invited speakers — Renato Porto (Interfarma), Pedro Ivo Sebba Ramalho (Ministry of Health) and Igor Bueno (FINEP) — brought important perspectives on the role of investments in the oncology sector.
According to Dr. Pedro Ivo, speaking on behalf of the Ministry of Health:
“We have some great opportunities to improve this environment and to make us increasingly capable of carrying out projects of this nature, speaking specifically of oncology research, and one of those opportunities is for us to better qualify institutions and at the same time publicize the program and the forms of access to the program, which also includes the collection of donations for the projects.”
We quote the position of Dr. Carlos Barrios who spoke out:
“I think that the country lacks, from a political point of view, strategies that are not only stable, continuous, that have a future and that people know that there will be a call in the month of November, there will be a call in the month of January and that people can prepare themselves, because the instability of the process and the complexity and the lack of disclosure, eventually compromise the access process and the objective that the government has.”
Also according to Dr. Barrios:
“It's a matter of maturation, the process of support that may come from the government I would think more about structuring within the government that was more uniform, clearer to understand, more predictable and obviously continuous and, recognizing the difficulties and the minimum participation that Brazil has in international clinical research, if the government would not have at least part of those resources to allocate funds to support research structures.”
During the debate, Dr. Igor Bueno made his statement:
“If we succeed now, with this predictability, this continuity, we are able to know what is necessary, strategic and what is the focus, I think it is fundamental, and forums like this are fundamental for us to be able to understand the public and the plaintiff. The public sector with its initiatives, FINEP with its public call, operating the fund and, what is the need of the industry, what is the need of the researcher. By talking, we are able to meet what FINEP will support and the demand of the institutions, this is the challenge since we have this predictability and continuity of a stable resource to support research.”
Also during the debate at the 5th Cura Meetings, Dr. Fábio Franke states that:
“The rules (about research) are not yet clear, which is why regulation is urgent, so that we can have clearer rules and attract more research, train more researchers and have proposals. And that is the purpose of Cura, proposals that answer our local questions, studies that demonstrate the reality of our population, that have an enormous and extremely interesting ethnic diversity, that we can make protocols that are more inclusive, that we can use this data and that knowledge for the advancement of the SUS, which will then be able to better define public policy strategies. So, everything is interconnected, but if we don't reduce the bureaucracy of the system and create clear rules, we will always continue to face the same difficulties.”
In his participation during the debate, Dr. Renato Porto said that:
“Regarding regulations, Brazil had no legal framework for clinical research, and now we do. We have difficulty regulating, in fact there are some situations, and speaking in a very synthetic way, we still have a cultural perception of what clinical research and scientific testing are very poor in the country and maybe that's a bit of the fact that we haven't done research over the past few years, so we need to start at some point and start quickly.”
The Cura Project Institute thanks the moderator Dr. Heloisa Magda Resende, President of the institution's Scientific Committee, and the debaters Dr. Carlos Barrios and Dr. Fabio Franke, who enriched the discussions with their experiences. Fernanda Schwyter, president of the Cura Project Institute, highlighted the relevance of this event as an essential space for exchange and collaboration.
The 5th Cura Meetings reinforced the commitment to expand access to science and innovation in Brazil, promoting opportunities for new research to become feasible. The full content of the event is now available on YouTube for those who wish to delve into the discussions and reflect on the future of oncology in the country.
.jpeg)
.jpeg)
.jpeg)
.jpeg)
Do you want to watch the full debates? Access the full event on YouTube
Link: https://www.youtube.com/watch?v=GmnKpwDIVZQ
Instituto Proyecto Cura is present at the 25th SBOC Congress with emphasis on advocacy in oncology
On November 7th, Fernanda Schwyter, president of the Cura Project Institute, participated as a speaker at the 25th Congress of the Brazilian Society of Clinical Oncology (SBOC), in the session “The relevance of advocacy actions in oncology: access & clinical research”. During her presentation, Fernanda highlighted the importance of non-governmental organizations (NGOs) in raising society's awareness of the benefits of clinical research and its impact on access to innovative treatments.
The event also included a moment of celebration, during which Fernanda met with members of the Scientific Committee of the Cura Project Institute, reinforcing partnerships and the exchange of knowledge between specialists in the field.
The Cura Project Institute thanks SBOC for the invitation and the opportunity to contribute to such relevant discussions, reaffirming its commitment to innovation, research, and access to health for all.
.jpeg)
.jpeg)
.jpeg)
.jpeg)
About the Cura Project Institute
The Cura Project Institute is a non-profit organization dedicated to raising awareness and funding clinical research in Brazil, working for 10 years to expand access to innovative treatments and combat cancer. More information is available on the Institute's website and on social networks: Instagram, Facebook, YouTube and LinkedIn.
Event brings together leaders from medicine, government, civil society and the pharmaceutical industry to discuss a coalition for clinical research in the fight against cancer
The Cura Project Institute will hold the 5th edition of Cura Meetings, an event integrated with the 25th Congress of the Brazilian Society of Clinical Oncology (SBOC), to discuss the topic “Financing clinical research: a coalition of medical and civil society, government and the pharmaceutical industry in favor of clinical research.” The meeting will take place on November 8, 2024, from 14:30 to 16:15pm, in room IBIZA II at Windsor Oceânico, and will bring together important names in health, research, government and the pharmaceutical industry to discuss the relevance of the union between sectors to strengthen the funding of oncological research in Brazil.
The event will be an exclusive space for professionals enrolled in the SBOC Congress and will address the challenges and opportunities of leveraging funding for clinical studies, with the objective of making Brazil a center for innovation and development in oncology. In the program, experts will discuss how collaboration between civil society, the private sector and the government can boost clinical research in the country and ensure that innovative treatments are available to more Brazilians.
Schedule — 5th Cura Meetings | Cura Project Institute
Schedule:
About the Cura Project Institute
The Cura Project Institute is a non-profit organization that promotes awareness and fundraising for independent clinical and academic studies in the area of oncology, aimed at combating cancer in Brazil. For 10 years, the Institute has been leading research support and encouraging the engagement of health professionals and civil society in funding studies, seeking to expand access to innovative treatments for Brazilian patients. More information is available on the Institute's website and on social networks: Instagram, Facebook, YouTube and LinkedIn
Service:
“Care Begins with Information”, will be the focus of the Pink October 2024 Campaign of the Cura Project Institute
The Cura Project Institute once again joins the Pink October Campaign, reinforcing the importance of raising awareness and preventing breast cancer. In 2024, the central theme of our campaign will be “Care begins with information”, a call to reflection on how knowledge can save lives.
Each year, thousands of women face the challenge of breast cancer. However, with access to the right information, the path from diagnosis to treatment can be clearer and less lonely. The purpose of our campaign is to disseminate quality knowledge, empower women and their support networks, and highlight the fundamental role of health professionals in this process.
Cura Talks Breast - an information event
One of the pillars of this year's campaign will be Cura Talks Breast, an event that brought together renowned experts, patients, and activists to discuss advances, challenges, and experiences in the fight against breast cancer. The event, which took place on August 29 during the 18th Gramado Breast Cancer Congress, went beyond the sharing of technical data — it was a space for dialogues that promote hope and action.
Speakers and debaters had varied topics, from new diagnostic methods and treatments to exchanges of experiences and stories from influencers and journalists.
According to the President of the Cura Project Institute, Fernanda Schwyter:
“Our goal is to use the Cura Talks Breast event and its highly relevant topics in this year's Pink October campaign, showing that, in addition to science and medicine, self-care begins with access to information.”
The Power of Information in Women's Health Care
Throughout the month of October, the Cura Project Institute will share educational content about breast cancer, covered in Cura Talks Breast, including:
In addition to providing access to essential information, we want to create a support network that amplifies the awareness message. We encourage the public to interact, share their stories, and learn from the experts.
The Cura Project Institute invites society to follow our actions during Pink October. Care begins with information, and together we can create a more aware, stronger, and supportive community. Information is the starting point for a future where breast cancer is detected and treated early, allowing more lives to be saved.
In this Pink October, let's reaffirm: care begins with information.
Last August 29th, Gramado in Rio Grande do Sul hosted Cura Talks Breast, an event conceived by the Cura Project Institute, held in parallel with the 18th Gramado Breast Cancer Congress and which brought together more than 50 guests and participants, including representatives of patient organizations, health professionals, journalists and influencers. With nearly 10 hours of intense programming, the event was a success, providing valuable insights into the importance of clinical research and advances in breast cancer treatment and care.
The day began with Catia Duarte, Counselor of the Cura Project Institute, who presented general information and guidelines for the participants. Then, Fernanda Schwyter, President of the organization, kicked off the activities with an inspiring opening, preparing the ground for the discussions that followed.
Between the moments of the panels, oncologist Dr. Pablo Barrios brought an in-depth view of the complexity of breast cancer in his lecture “Breast Cancer: Who Are You?”. Soon after, mastologist Felipe Zerwes highlighted the importance of early diagnosis in the evolution of treatment, presenting an overview of the current scenario and the challenges faced.
One of the highlights of the event was the debate that brought together representatives of important organizations such as Camaleão, Femama, Américas Amigas and AMUCC. For one hour, the participants discussed advances and challenges in the field of breast oncology, enriching the event with different perspectives.
After a brief break, Dr. Heloisa Resende discussed the relevance of clinical research and the importance of regulation, followed by a debate moderated by Fernanda Schwyter. The highlight of the morning was the roundtable with influencers such as Claudia Bartelle, Jussara Del Moral, Carol Magalhães and Gi Charaba. They shared their experiences and discussed the impact of onco-influencers in the dissemination of information about breast cancer, generating profound reflections among those present.
In the afternoon, interactive sessions brought up questions about inequalities in access to breast cancer treatment and the importance of the topic on the political agenda and in the interest of civil society. The lectures given by Dr. Ana Amelia Viana, Dr. Fernanda Bairros, Mônica Leal, and Cíntia Seben were especially impactful, providing rich and enlightening discussions.
Another important moment was the discussion about the journey of metastatic patients, conducted by renowned oncologists Dr. Carlos Barrios and Dr. Gustavo Werutsky. They addressed the issue of patients' longevity and quality of life, bringing a new perspective on survival to metastatic breast cancer.
.jpeg)
In her session, Dr. Alessandra Morelle addressed the impact of new technologies and artificial intelligence on the treatment of breast cancer, pointing to the future of oncology.
The event ended with a special session, where journalists Cristina Ranzolin, Alice Bastos Neves and Duda Streb shared their perspectives on the dissemination of information about breast cancer in the media, providing an inspiring and informative closing.
Cura Talks Breast 2024 has established itself as an essential space for the exchange of knowledge and experiences, reaffirming the commitment to the advancement of breast cancer research and treatment in Brazil. The recording of the event will be available on the Cura Project Institute's social networks, allowing the discussions to continue to reverberate and reach an even larger audience.
Watch Cura Talks Breast Gramado.
O Cura Talks Breast Gramado it was undoubtedly a milestone in the promotion of research and knowledge in oncology, reinforcing the importance of joining efforts to ensure continuous advances in the fight against breast cancer.
With the mission of promoting clinical research in favor of oncology, the Cura Project Institute, with Cura Talks Breast Gramado, reaffirms its commitment that healing begins with research, and that research saves lives.
In the photo: Fernanda Schwyter, President of the Cura Project Institute; Dr. Felipe Zerwes, Dr. Carlos Barrios and Dr. Antônio Frasson, creators of the Gramado Breast Cancer Congress; and Cátia Duarte, Counselor of the Cura Project Institute.
Cura Talks Breast was sponsored by: Daiichi Sankyo, Lilly, MSD, and Novartis.
Advances in treatment, which are changing patients' outlook on life, will be discussed at Cura TALKS Breast Gramado - a free event open to the public - on August 29th
“We have to change our perception of metastatic breast cancer in view of what we have in terms of advances in management and treatment. Everyone's job is to give light and attention to those patients that until now were hidden,” says oncologist Dr. Carlos Barrios, who is director of the Latin American Group for Clinical Oncology Research (LACOG). The expert's lecture is one of the highlights of the event. According to the doctor, in recent years, women with metastatic cancer are living longer and some of them have even been able to cure the disease. Some of the new medications are now available in the SUS.
The participation of Brazilian women in research is one of the flags defended by Cura, which is why one of the highlights is the panel Navigating the individual profile of patients on their breast cancer journey. One of the speakers will be the Bahian doctor Dr. Ana Amélia de Almeida Viana, from the Diversity Committee of the Brazilian Society of Clinical Oncology. According to the expert, black women die more from breast cancer in Brazil, and one explanation is that black women are diagnosed with breast cancer at more advanced stages of the disease, making treatment difficult. “The problem is that the black population in our country has less access to diagnostic tests and specialized treatment. Besides, it's rare to see black women represented in campaigns. That's why many find it difficult to see that the message of the importance of health care is for them too.”
Cura TALKS Breast Gramado, designed by the Cura Project Institute, will be held as a parallel program to the 18th Gramado Breast Cancer, an exclusive paramedical congress. Some of these specialists will also participate in the Cura Talks Breast talks.
The dissemination of secure information, avoiding fake news, is another concern of the event. For this reason, journalists and influencers were invited to participate in round tables. Among them, Claudia Bartelle, from Rio Grande do Sul, who has had breast cancer. “Our role is extremely important, because since we influence, we have to do it with purpose. Since we can influence it to be for good and to make women aware that women need to take care of themselves and pay attention to their bodies. It's important to remember that we have a health schedule. The speech of each one of us can save many lives. That's my role in the social network,” she says. The closing theme, on the other hand, will be the Mama CA Patient and the information through the eyes of those who report the news. Journalists Cristina Ranzolin, Alice Neves and Eduarda Streb will participate.
About the Organization of the Event: The Cura Project Institute is a non-profit organization dedicated to making society aware of the benefits of clinical research. The entity, which is at the forefront in Latin America, encourages health professionals to be researchers and raises funds to finance independent scientific or academic studies, through the promotion of scientific, sporting or social events. The organization also receives donations from individuals or legal entities - directly or indirectly - through the donation or deduction of income taxes, for example.
Service: Cure TALKS Breast Gramado
Date: 29.08.24 - from 9 a.m. to 6 p.m.
Target audience: patient organizations, journalists, digital influencers, and the general public
Venue: Hotel Serrano - Av. das Horténsias, 1480
Free registrations for in-person participation on the site: https://www.sympla.com.br/evento/cura-talks-breast/2545649
Press Office:
Melissa Gass - 51 99573.5372
Flávia Marroni - 51 99877.8913
Free event open to the public - Cura TALKS Breast Gramado - brings renowned experts to discuss new treatments and the importance of safe sources about the disease
Breast cancer is the leading cause of cancer death in women in the country. Therefore, it is important to encourage academic clinical research. The president of the Cura Project Institute, Fernanda Schwyter, organizer of the event, points out that
“we need to know our population and carry out more studies to answer questions about the incidence of the disease in our population so that we can learn more about the peculiarities of the disease faced by so many Brazilian women”.
Cura TALKS Breast Gramado will be held as a parallel program to the 18th Gramado Breast Cancer, an exclusive congress for doctors. Some of these specialists will also participate in the Cura Talks Breast talks, presenting advances in treatments, including metastatic cancer.
Another focus of the meeting will be the discussion about the importance of disseminating reliable content, avoiding fake news and disservices. For this reason, opinion leaders - press, patient entities and digital influencers - are the target audience of Cura TALKS Breast Gramado.
Statistics: According to the Ministry of Health, in Brazil, excluding non-melanoma skin tumors, breast cancer is the most common in women in all regions, with the highest rates in the South and Southeast regions. For each year of the triennial period 2023-2025, 73,610 new cases were estimated, representing an adjusted incidence rate of 41.89 cases per 100,000 women (INCA, 2022).
The Cura Project Institute is a non-profit entity dedicated to making society aware of the benefits of clinical research. The entity, which is at the forefront in Latin America, encourages health professionals to be researchers and raises funds to finance independent scientific or academic studies, through the promotion of scientific, sporting or social events. The organization also receives donations from individuals or legal entities - directly or indirectly - through the donation or deduction of income taxes, for example.
.jpeg.jpeg)
Service: Cure TALKS Breast Gramado
Date: 29.08.24 - from 9 am to 6 pm
Target audience: patient organization organizations, journalists, digital influencers, and the general public
Venue: Hotel Serrano - Av. das Horténsias, 1480
Free registrations for in-person participation on the site: https://www.sympla.com.br/evento/cura-talks-breast/2545649
The Prize designed by the Cura Project Institute, a non-profit organization, was created to pay homage to Renata Thormann Procianoy, stimulate philanthropy and recognize researchers in the field of oncology, encouraging the increase of academic studies in Brazil. This year, the winner of the 6th Edition of the Prize was announced on June 22nd in São Paulo.
Winner of the 6th Edition of the Renata Thormann Prociany Prize
The winner of the Renata Thormann Procianoy Prize in 2024 was the HERCULES Study, with Dr. Fernando Maluf as principal investigator, developed in research centers across Brazil.
Coordinated by Lacog Cancer Research - LACOG, the study pointed out a new path for the treatment of advanced penile cancer, with immunotherapy associated with chemotherapy. The results so far are impressive: 33 patients tested since 2020, of which 75% of them experienced some reduction in tumor volume and 39.4% showed significant reduction.
The award was presented by the president of the Cura Project Institute, Fernanda Schwyter, together with doctors Fabio Franke and Antonio Buzaid, to Dr. Fernando Maluf, during the 1st Symposium on the Overcoming Cancer Clinical Research Network, organized by Overcoming Cancer.
A new feature of the 6th Edition of the Prize is that I mentioned the second ranked study in recognition of the second place, reinforcing the need to stimulate and encourage new researchers in the fight against cancer. The recognition award was awarded to Dr. Maria Cecília Mathias for the Study: impact on the survival of KRAS mutations in first-line metastatic colorectal cancer (Abstract number: 3547 - Institution: ICESP)
The award is an inspiring love story
The story behind the award is profoundly touching. Nora Thormann, a psychiatrist, faced a health problem and could not find an effective treatment within existing protocols. However, her daughter Renata Thormann Procianoy, knowing the importance of research, searched for innovative studies for two years that could help her mother. This search resulted in the inclusion of Nora in a clinical study coordinated by Dr. Roberto Miranda, at the MD Anderson hospital at the University of Texas, in the USA. The research sought to understand the relationship between breast implants and some rare types of breast cancer. And so Nora had a remission of her illness.
Unfortunately, a few months after Nora's cure, Renata suffered a car accident and died. Nora's testimony can be seen below:
https://www.youtube.com/watch?v=ohLeWAOaBkg
History of previous winners
2019: Dr. Thiago Bueno de Oliveira
The first winner of the Renata Thormann Procianoy Prize was Dr. Thiago Bueno de Oliveira. His innovative research focused on the evaluation of circulating tumor cells in patients with head and neck cancer, offering new perspectives for the monitoring and treatment of this condition.
2020: Dr. Fernando Maluf
In 2020, Dr. Fernando Maluf was awarded for his study on a new drug for the treatment of advanced prostate cancer. The research, conducted at 14 research centers in Brazil, stood out for its promising results and its potential impact on the lives of many patients.
2021: Dr. Luciana Landeiro
Dr. Luciana Landeiro was the 2021 winner with her study on the use of electric hand warmers to reduce discomfort during scalp cooling. This technique aims to prevent chemotherapy-induced alopecia, improving patients' quality of life during treatment.
2022: Dr. Verônica Torres
In 2022, Dr. Verônica Torres was recognized for her study on the 2021 CKD-EPI equation without racial coefficient in adults with solid tumors. His research brought important insights for the assessment of renal function in cancer patients, promoting a more inclusive and accurate approach.
2023: Dr. Fernanda Bronzon Damian
The most recent winner, in 2023, was Dr. Fernanda Bronzon Damian. His Lacog 1018 study was highlighted during the Best of Asco 2023 - Brazil Edition, demonstrating significant advances in cancer treatment and reaffirming the importance of continuous and innovative research.
The Scientific Committee responsible for evaluating and judging the Brazilian studies presented at ASCO 2024, which took place in Chicago between May 30 and June 4, is composed of renowned oncologists. In alphabetical order, the members are: Dr. Abna Vieira, Dr. Max Mano, Dr. Cristiano de Pádua Souza, Dr. Eduardo Romero, Dr. Fernando Moura, Dr. Guilherme Harada, Dr. Mariana Scarantini and Dr. Pedro Neffá.
According to Fernanda Schwyter, founder and president of the Cura Project Institute: “It is a great pleasure to stimulate the development of scientific knowledge in the country, to collaborate with the improvement of treatment worldwide, and to improve the outcome of patients' quality of life.”
The Renata Thormann Procianoy Award is an important tribute to researchers and researchers for their dedication and innovation in the field of oncology. It pays homage to the memory of Renata Thormann Procianoy, encourages and recognizes the efforts of researchers who are at the forefront of the fight against cancer, contributing to a future where more accurate diagnoses and more effective treatments are a reality for everyone.
Now, the Bill has become Law 14,874/2024.
On May 26, 2024, the President of the Republic signed Bill 6007/2023, now known as Law 14,874/2024, which establishes guidelines on research with human beings and establishes the National System of Ethics in Research with Human Beings. The publication in the Federal Official Gazette — DOU, marks a significant advance in the regulation and ethics of clinical research in Brazil. However, two points of the Bill were vetoed and are subject to deliberation by the National Congress within 30 calendar days:
Paragraph 3 of art. 24 of the Bill - The need to report to the MP the participation of members of indigenous groups in research: “Despite the good intention of the legislator, the provision, by providing that the participation of members of an indigenous group in research must be reported to the Public Prosecutor's Office, violates the principle of equality and points to the possible situation of state protection in relation to indigenous peoples, a condition that has already been overcome by legislation.”
Section VI of art. 33 of the Bill - The end of the supply of experimental drugs to patients after 5 years of their commercial availability in the country: “Despite the good intention of the legislator, the legislative proposal is contrary to the public interest by establishing a period of five years for the continuation of the free supply of the experimental drug after the closure of the study”.
The sanction of Law 14,874/2024 represents an important step for ethics and regulation in clinical research, and the Cura Project Institute will continue to work tirelessly to promote health and well-being through research, remaining aware of the consequences of this law in the National Congress and will release any relevant news.
Reflections from the Cura Talks event - May
Bill 6007/2023 was sanctioned shortly after the Cura Talks - May Research Month event, held on May 21 in São Paulo. The event, organized by the Cura Project Institute in partnership with the Brazilian Society of Clinical Oncology (SBOC), continued the theme “Regulatory Pathways of Clinical Research in Brazil”. This was a fundamental space to discuss and understand the rights of research participants within the framework of the Bill.
Cura Talks Maio was attended by lawyers Angela Kung and Anna Luiza Bertin, both rapporteurs of the Research Ethics Committee of the Federal University of São Paulo (CEP/UNIFESP). They provided a detailed overview of the legal and ethical aspects of clinical research in Brazil, highlighting the benefits that these changes will bring to the health system. Fernanda Schwyter, President of the Cura Project Institute, was the host and mediator of the event, which was also welcomed by the President of SBOC, Dr. Marisa Madi.
May is the month of awareness about Clinical Research and the Cura Project Institute, in this month and every other month of the year, is committed to promoting events that inform and educate society about the importance of clinical research and the rights of participants.
If you missed the Cura Talks Maio broadcast or want to review the most important moments, the recording is available on our YouTube channel. Don't miss this opportunity to get up to date on a topic so relevant to the advancement of science and health in Brazil.
https://www.youtube.com/watch?v=_B3EAQ5epZM&t=326s
The Cura Project Institute remains committed to following and disseminating all updates regarding Law 14,874/2024 and the impacts it will bring to the future of clinical research in the country.
Cura's commitment to Clinical Research
The events promoted by the Cura Project Institute, such as Cura Talks, Cura Meetings, as well as initiatives such as the Research Save Lives Movement, play an essential role in disseminating information and raising awareness about the importance of clinical research. These actions educate the public about advances and challenges in the area of health, in addition to promoting active community, lay and medical engagement, encouraging participation and support for research.
We, members of the Cura Project Institute, a cutting-edge institution in Latin America, are happy to see our work being understood by society and achieving its objectives, leading the mission of strengthening and expanding clinical research, contributing significantly to scientific progress, improving the quality of life of cancer patients and increasing resources for funding academic studies in the region.
The Cura Project Institute has been active in defense of the benefits of clinical research for the entire health system in Brazil and the need to expand patients' access to clinical studies. For almost 10 years, we have supported the funding of 11 researches, on different types of tumors.
In recent months, we have been attentive to understanding and enlightening the population about important points of Bill 6007/23, which will regulate clinical research in Brazil, since rights and obligations are guaranteed in our country, through laws.
In the midst of challenges, we share the approval of Bill 6007/2023, a framework for the regulation of research in Brazil.
In Brazil, laws are the foundation that underpins our rights and duties. And when it comes to science and research, regulation is fundamental to ensure safe and ethical advances.
The recent milestone approval of Bill 6007/2023 is an example of this. This Law is essential for the regulation of clinical research in our country, establishing clear guidelines and protecting both participants and researchers.
In this path towards approval, the role of the Cura Project Institute was fundamental, as it led efforts to implement it and clarified the important points of the bill and, through approaches to Social Networks, interventions with government agencies and events such as Cura Talks — Regulatory Pathways of Clinical Research in Brazil, which took place on March 15 in São Paulo (Event link: https://www.youtube.com/watch?v=4EtyifKKOQE&t=4981s). In this process, Cura has also demonstrated its commitment to ensuring that patients have equitable access to clinical research opportunities.
We strongly defend that “Research saves lives”. For this reason, it is essential to have legislation that guarantees rights and duties in the area of scientific research in Brazil, guaranteeing the safety, ethics, and quality of the studies carried out.
The Cura Project Institute plays an important role in defending patients' access to clinical research in oncology in Brazil. For almost 10 years, Cura has stood out for its dedication to promoting an ethical and accessible culture of clinical research, and to the awareness and education of civil society, informing about their benefits for the health system, how they drive medical innovation and have the potential to transform lives.
Points that highlight how laws play a fundamental role in the regulation of clinical research in Brazil:
Participant protection: Regulation through laws establishes clear guidelines to ensure the safety and well-being of clinical trial participants. This includes informed consent protocols, monitoring for adverse events, and guarantees that participants are treated with dignity and respect.
Ethics in research: The laws provide an ethical framework to guide the conduct of clinical research. They define ethical and moral standards that researchers must follow, ensuring that research is conducted in a fair, transparent manner, and with scientific integrity.
Quality of studies: Regulation through laws helps ensure the quality of clinical studies, establishing standards for study design, data collection and analysis, and dissemination of results. This contributes to the reliability and credibility of the research carried out in the country.
Promotion of innovation: By providing a stable and predictable regulatory environment, laws can attract investment and collaboration, driving advances in the area of health.
International alignment: The laws that regulate clinical research in Brazil can ensure that the country is aligned with international standards of good clinical practice. This facilitates collaboration with foreign researchers and institutions, promoting knowledge exchange and participation in multicenter studies.
Public trust: Robust and transparent legislation increases public trust in clinical research. By knowing that research is conducted according to ethical and legal standards, individuals may feel more comfortable participating in clinical studies and supporting science as a whole.
We are now facing a new chapter, where the regulation of clinical research will be anchored in a law. We will closely monitor this process and continue to promote information and awareness of civil society, through our actions, events and campaigns, with the purpose of a culture of ethical and responsible science in our country and, especially, demonstrating the commitment of the Cura Project Institute to responsible science and to the well-being of all.
The Cura Project Institute, with the participation of important health stakeholders, celebrates the success of the 2nd Cura Talks, held on March 15 at the InterContinental Hotel in São Paulo. The event, which attracted a diverse audience, in person and online, was an important channel to discuss the advances and challenges of clinical research in oncology in Brazil.
The topic “Regulatory paths of clinical research in Brazil” highlighted the understanding of the paths of Bill 6007/23 and its consequences in clinical research. Since Brazil has made significant progress in this regard, the purpose of the event was to seek to understand and encourage an environment that is more conducive to the development of clinical studies and access to new therapies.
During the 2nd Cura Talks, experts highlighted the importance of clear and agile ethical regulations that promote the safety of study participants and optimize the approval process for new therapies. In addition, the need for tax incentives and adequate funding to boost clinical research in the country was highlighted.
The event also provided a valuable space for the exchange of experiences between researchers, health professionals, lawyers, patients, and support networks, highlighting the fundamental role of multidisciplinary collaboration in the advancement of clinical research in oncology.
The opening of the 2nd Cura Talks was held by the President of the Cura Project Institute, Fernanda Schwyter, who mentioned that:
“In this 2nd Cura Talks we will understand the changes that will take place in the field of clinical research, after the approval of Bill 6007/23 for all diseases, not just cancer, and after approval, we will be able to organize ourselves to implement actions necessary for the proper development of clinical trials and guarantee the rights of research patients.”
The importance of clinical research
With an introductory approach to the 2nd Cura Talks, Dr. Carlos Barrios, Director and Principal Researcher of the Oncology Research Center at PUCRS São Lucas Hospital, covered a discussion about the importance of clinical research and its impact on patients. Dr. Barrios emphasized that clinical research is an activity that involves multiple dimensions, including scientific advances, development of new drugs, social impact, and improvements in health services. He emphasized that institutions with research centers tend to offer better care to all patients, not just study participants, due to improved routines and the development of best practices.
Two examples were shared to illustrate the benefits of clinical research. He highlighted that clinical research has the potential to reduce disparities in medical care internationally and offer access to state-of-the-art treatments, regardless of geographical location. In addition, he emphasized the importance of increasing the number of research centers and funding for regional research that addresses the specific needs of local populations.
Dr. Barrios concluded by reinforcing the idea that clinical research is a fundamental activity that directly benefits patients, promoting hope and offering access to innovative treatments. He emphasized the need to continue working to expand the reach of clinical research and ensure that it is accessible to all who need it.
The next steps for implementing Bill 6007/23
Congressman Pedro Westphalen, obstetrician and Federal Representative, participated in the event as rapporteur of the bill that deals with clinical research on human beings in Brazil (PL 6007/23). He highlighted the importance of this project to streamline clinical research in the country, allowing patients to have faster access to innovative treatments. The project aims to unblock red tape and guarantee the quality and safety of research, allowing Brazil to become a research hub of excellence.
The congressman emphasized the urgency of the project, stressing that patients do not have time to wait for state bureaucracy. He emphasized the need to sensitize the Senate to the importance of the project and to guarantee its approval and presidential sanction. He also explained that, once approved and sanctioned, the law will be valid immediately and regardless of political changes in the government. He also answered questions about the regulation of the project after its approval, stating that the government must implement it without delay.
With regard to regulations, Westphalen advocates that the CEP/CONEP system be directly linked to the Ministry of Health. Regarding the administrative steps after the approval of the law, the Deputy emphasized the importance of pressure and mobilization of society to ensure its effective and rapid implementation. He highlighted the willingness to discuss possible adjustments to the project, as long as they do not mischaracterize its main purpose.
Finally, Westphalen thanked the opportunity to participate in the event and made himself available to collaborate with the project, highlighting the importance of the Cura Institute and the engagement of all those involved in the promotion of clinical research in Brazil.
Stories that inspire Cura
The mother of a clinical research patient, Alessandra Santos, shared her experience during the 2nd Cura Talks. Her daughter began to show symptoms, complaining of pain in her left thigh, which soon became disabling. After going through three hospitals and several treatments without success, she was admitted and diagnosed with a condition related to rectocolitis, an inflammatory bowel disease. Later, she participated in a clinical study, her daughter's life changed for the better.
She now lives a normal life, with minimal side effects from treatment. Alessandra expressed her gratitude for the study and emphasized the importance of publicizing clinical research. She recognized that while there is no cure for rectocolitis, proper care and treatment are essential. Alessandra also highlighted the need to support families during the clinical research process. She encouraged others to seek clinical studies and emphasized the importance of being informed about treatment options. His message highlighted gratitude for the opportunity to participate in the event and share his story, highlighting the importance of clinical studies in improving health and in the search for effective treatments.
Papo Cura
Papo Cura during the 2nd Cura Talks was a debate between Luana Ferreira Lima, Dr. Angela Kung, Dr. Carlos Barrios and the audience present and online, mediated by Fernanda Schwyter. The discussion addressed topics such as research, regulation, and the participation of society in this process.
The introduction highlighted the importance of understanding and absorbing the information presented. Dr. Barrios was invited to talk about the relationship between international research and research carried out in Brazil, while Dr. Angela Kung, a specialist in health law and member of the CEP/CONEP system, brought her expertise on the subject. Luana Ferreira Lima, representative of civil society organizations, TJCC (All Together Against Cancer) also participated, bringing the patients' perspective and the need to include them in the research process.
It was clarified that research is not only carried out by pharmaceutical industries, but also by academic institutions and researchers and the importance of including patients in the decision-making process. A study by Dr. Heloisa Resende was mentioned, revealing that a minimum percentage of cancer patients are invited to participate in research by doctors, pointing out the need for awareness in this regard.
Sponsors: Latin American Cooperative Oncology Group - LACOG, DAIICHI Sankyo Brazil and MSD.
Support: ABRACRO, ABRALE, Oncology Observatory and All Together Against Cancer, Overcoming Cancer and Life Time.
The full recording of the 2nd Cura Talks is available for viewing on the YouTube channel:
https://www.youtube.com/watch?v=4EtyifKKOQE
For more information about the Cura Project Institute, visit the official website: https://projetocura.org/
The Cura Project Institute will remain committed to promoting dialogue, education, and progress toward a more informed and engaged society. We look forward to having everyone's continued participation and support in our future initiatives.
Finally, the Cura Project Institute would like to express its sincere gratitude to the speakers, moderators, the Cura Team, and to the audience present and online, whose engagement and support were essential for the success of the 2nd Cura Talks. In addition, Cura records thanks to sponsors and support partners, whose support was fundamental to making this event possible.
The Cura Project Institute will hold, on the 15th, Cura Talks, which is an event that aims to provide guidelines for the challenges faced by cancer patients in Brazil and to provide a space for information and awareness on important topics, especially related to clinical research in oncology.
Cura Talks, which takes place in a hybrid form on March 15, 2024 in São Paulo, focuses on current and relevant issues that directly impact the quality of life and outcomes of cancer patients, as well as their support networks.
The purpose of the Cura Project Institute is to inform and make society in general, which includes health professionals, leaders of patient associations, patients, family members and all those interested in the fight against cancer, aware of various aspects of oncology, with special attention to clinical research. By doing so, we hope to empower participants to better understand the current cancer research landscape, its advances and challenges, and how this translates into tangible benefits for patients.
With the theme “Regulatory Pathways of Clinical Research in Brazil”, this edition of Cura Talks will explore Clinical Research and the regulations surrounding it in the country.
Check out the confirmed speakers:
Fernanda Schwyter - Founder and President of the Cura Project Institute
Dr. Carlos Barrios - Director and Principal Researcher of the São Lucas Hospital Oncology Research Center at PUCRS. Director of LACOG - Latin American Cooperative Oncology Group. Physician and Clinical Research Coordinator of the Oncoclinics Group. One of the most cited researchers in the world in 2023 - “High Cited Researchers 2023”
Congressman Pedro Westphalen - Physician and Parliamentarian, rapporteur in the Chamber of Deputies in 2023 of Bill 7082/2017, which was approved and provides for clinical research with human beings.
Luana Ferreira Lima - Lawyer, specialist in humanitarian action from the University of Geneva, master's degree in human rights from the Federal University of Minas Gerais, Public Policy and Advocacy Coordinator of the Brazilian Lymphoma and Leukemia Association (ABRALE) and Coordinator of the All Together Against Cancer Movement (TJCC) — Representing 300 Brazilian NGOs.
Cura Talks is an important event for a better understanding of clinical research in oncology, empowering individuals and communities to face this challenge more effectively and compassionately, bringing up-to-date knowledge and information, in addition to promoting an open and constructive dialogue aimed at continuously improving access to treatments for cancer patients.
Target Audience:
Cura Talks is aimed at a wide variety of participants, including health professionals, researchers, patient association leaders, cancer patients, their families and caregivers, as well as anyone interested in learning more about the fight against cancer and the crucial role of clinical research.
Don't miss the opportunity to participate in Cura Talks. Join us on March 15, 2024, at the Intercontinental Hotel in São Paulo, or participate virtually through the online platform.
For more information and registration, visit the event link: https://www.sympla.com.br/evento/cura-talks/2332503
We look forward to welcoming you to Cura Talks! Join us on this journey of learning and collaboration.
About the Cura Project Institute
The Cura Project Institute is a non-profit institution, created in 2016, dedicated to making society aware of the benefits of clinical research and addressing its importance for advances in cancer treatment, a topic of extreme relevance to public health and quality of life of the population of Brazil and other Latin American countries. The Institute develops activities aimed at advising patients, lay people, health professionals and government agencies about the importance of clinical research. Learn more by accessing the site: www.projectocura.org.br
On February 4th, the world came together in an essential awareness campaign: World Cancer Day. This date, marked on the global calendar, is an important reminder of our collective responsibility to address this disease more effectively and compassionately.
This year, the Cura Project Institute Joined the campaign of International Union for Cancer Control (UICC), whose theme is “For fairer care”. It's a call to action, a call to ensure that everyone, regardless of their socioeconomic or geographical situation, has equal access to the best care and treatment available.
“World Cancer Day reminded us of the global cancer emergency and how we all play our part in controlling the disease.” Ebele Mbanugo, Doctor of Education - Founder and Executive Director of Run For a Cure Africa
In accordance with this commitment, the Cura Project Institute highlights the importance of clinical oncology research. The phrase that Cura summarizes for this mission is: “Clinical Research saves lives and in many cases it's the only way to guarantee access to innovative technologies”. It is essential to understand that clinical research is not just a distant scientific investigation: it is a vital bridge between medical discovery and accessible and effective treatment for patients.
By launching a series of UICC informational materials, Cura aimed not only to raise awareness of the importance of clinical research, but also to highlight how these investigations are crucial for significant advances in cancer treatment. Each breakthrough in research is a new hope for those who face this disease, offering alternatives, new treatments, and technologies.
GO BY THE HANDKERCHIEF CAMPAIGN - ABRALE
In addition to the global campaign and, in solidarity with cancer patients, the Cura Project Institute supported, for another year, the Abrale (Brazilian Lymphoma and Leukemia Association) campaign, the “Go with the handkerchief”. We recognize the importance of showing support to those who are treating and living with cancer, and wearing a handkerchief was a way to express our empathy and support. This was a visible reminder that no one is alone on this journey and that we are united in the search for better care, treatment, and healing.
In this month that World Cancer Day was celebrated, our team invited everyone to join us, both in raising awareness about the importance of clinical research and in supporting patients and their families. Together, we can make a difference by promoting more just and compassionate care for all those affected by cancer.
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
The American Society of Clinical Oncology has published important new recommendations regarding genetic testing of BRCA 1/2 genes for breast cancer patients. Check out details.
The Journal of ASCO (American Society of Clinical Oncology) published some recommendations for patients diagnosed with breast cancer. These recommendations also apply to the family members of these patients..
Here's a summary of the recommendations cited in the article:
3. Patients who choose to undergo the BRCA1/2 test should also undergo testing for other cancer predisposition genes, as suggested by their personal or family history. Consultation with a professional with experience in clinical cancer genetics can help guide this decision-making and should be made available to patients when possible.
4. All patients diagnosed with recurrent (local or metastatic) breast cancer who are candidates for PARP inhibitor therapy should undergo the BRCA1/2 test regardless of family history.
5. The BRCA1/2 test should be offered to patients with a second primary contralateral or ipsilateral breast cancer.
6. All patients with a personal history of breast cancer diagnosed under the age of 65 and without active disease should be offered the BRCA1/2 test if the result informs personal risk management or family risk assessment.
7. All patients with a personal history of breast cancer diagnosed over 65 years of age and without active disease, who meet one of the following criteria, should take the BRCA1/2 test if the result is to inform personal risk management or family risk assessment:
8. Tests for high-penetrance genes other than BRCA1/2, including PALB2, TP53, PTEN, STK11, and CDH1, can help define the best medical therapy, influence surgical decision-making, refine risk estimates for a second primary cancer, and inform family risk assessment, and should therefore be offered to patients according to medical evaluation.
9. Testing for moderate penetrance breast cancer genes currently offers no benefits for treating the breast cancer index, but it can inform the risks of a second primary cancer or familial risk assessment and thus may be offered to appropriate patients who are undergoing the BRCA1/2 test.
10. If a multigene panel is requested, the specific panel chosen must take into account the patient's personal and family history. Consultation with a professional experienced in clinical cancer genetics may be helpful in selecting a specific multigene panel or interpreting its results and should be made available to patients when possible.
11. Patients undergoing genetic testing must receive sufficient information prior to testing and provide their consent.
12. Patients with pathogenic variants should receive individualized post-test genetic counseling and be referred to a professional experienced in clinical cancer genetics).
13. Genetic variants of uncertain significance should not alter the treatment definition. Patients should be informed that variants of uncertain significance can be reclassified as pathogenic and should understand that periodic follow-up is necessary. Consultation with a professional experienced in clinical cancer genetics may be helpful and should be made available to patients when possible.
14. Patients without a pathogenic variant in genetic testing may still benefit from counseling if there is a significant family history of cancer, and referral to a professional with expertise in clinical cancer genetics is recommended.
Link to publication: https://ascopubs.org/doi/full/10.1200/JCO.23.02225
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
The Cura Project Institute presents the companies that support the NGO in 2023.
In a world where the Journey against cancer it's a constant process, Cura Project Institute stands out as a important bridge between science and the patient, expanding awareness, education, and information about clinical research to combat cancer and encouraging fundraising for investment in academic studies.
In the year 2023, we look back with gratitude for the support that made, and will make possible, significant advances in cancer research and awareness.
The Cura Project Institute would not be able to fulfill its mission without the essential support of various institutions and individuals, and sees in each donation, the partnership and collaborative effort that have been fundamental to boosting our capacity to face cancer more effectively.
With this, we would like to express the importance of all the companies that supported the Cura Project in the last year: Prognostic Clinic, Cancer Institute of Brazil (ICB), Alta Saúde Home Care, ONE — Ocean Network, UMotivo Channel and The Magal Way. We also thank Breast International Group (BIG), LACOG, All Together Against Cancer and Brazilian Mastology Society for their institutional support.
We emphasize that each contribution is immeasurable, since the impact of research goes beyond what we can see translated into treatments. It is a support that leaves a mark on science and on the lives of everyone involved in this universe.
A Awareness-raising is a powerful tool in the fight against cancer. With the support of our partners, we were able to broaden the population's understanding of the importance of research and the challenges faced by those living with cancer. The dissemination of relevant information has been possible thanks to continuous collaboration with organizations committed to the cause.
Our big thanks to everyone! We will continue to fight, encourage research, and inspire hope until a cure is a reality for all.
Let's continue together to make 2024 even better!
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
In an effort to understand the clinical research landscape in oncology in Brazil, the CURA Project Institute conducted a scientific study in partnership with LACOG - Latin American Cooperative Oncology Group, entitled “Current scenario and future perspectives of clinical research in Brazil: a national survey”.
Led by the lead author, Dr. Heloisa Resende, Oncologist and Researcher, member of the Latin American Cooperative Oncology Group (LACOG) and President of the Scientific Committee of the CURA Project Institute, in collaboration with a team of renowned researchers, the study aimed to evaluate the current behaviors and future trends of Brazilian oncologists in relation to clinical research in the care of their cancer patients.
The initial segment of the research focused on gathering information about demographic details, medical education, and prior participation in research. The subsequent part addressed the main barriers to involvement and participation in clinical trials in Brazil.
The findings of this study were published in the renowned journal eCancer Medical Science, showing the importance of research in the scientific community, and Dr. Heloisa Resende played a fundamental role in advancing this initiative. Check out the publication by accessing the link.
A notable achievement was the acceptance of this research for publication at ASCO 2023, the annual congress of the American Society of Clinical Oncology, the largest gathering of oncology professionals in the world, held in Chicago, USA, on June 2.
Check out the video of Dr. Heloisa Resende (Jardim Amália Research Center) talking about the study “A national survey of the current scenario and future perspectives of cancer research in Brazil” presented at the ASCO Annual Meeting 2023.
https://www.instagram.com/p/CtZ0oMcrwy
The main findings of the research clarify the following aspects:
- Demography of the participating doctors: Most of the doctors involved in the study work predominantly in capital cities and are linked exclusively to private health services. 57% of the interviewees work in the Southeast region and 77% in the capitals.
- Communication on Clinical Research: 1/3 of the doctors interviewed refer less than 1% of your patients to participate in clinical research
- The results of the study suggest a clear need for greater involvement of doctors in clinical research activities in Brazil. Strategies for patient education are identified as crucial to improve low recruitment rates and, consequently, increase the number of proposed trials in the country.
Here is the summary of the publication “Current scenario and future perspectives of clinical research in Brazil: a national survey”
Contexts: Epidemiological and clinical cancer research is essential for understanding tumor behavior and the development of new therapies in oncology. However, several countries, including Brazil, as well as many other regions of the world, have limited participation in clinical studies on cancer. Although 625,000 new cancer cases were registered in Brazil in 2022, only 2.2% of ongoing cancer clinical trials are available in the country. We conducted an online survey to describe the involvement of doctors with clinical research and to identify the main barriers that prevent the participation and conduct of clinical studies on cancer in the country.
Methods: An anonymous online survey with 23 objective questions was sent by e-mail to Brazilian members of the Latin American Cooperative Oncology Group and the Brazilian Society of Clinical Oncology. The first 13 questions addressed demographic information, medical education, and previous participation in research. In the second part, the main barriers to engagement and participation in clinical trials in Brazil were discussed. Continuous variables were measured by median and amplitude. The analyses were performed using the SAS statistical software (version 9.4; SAS Institute, Inc. Cary, NC).
Results: 109 doctors answered the survey. Most of the participants were oncologists (N = 98, 89.9%), resided in capitals (N = 84, 77.1%), came from the Southeastern region of Brazil (N = 63, 57.8%) and worked in institutions that provided exclusively private care (N = 59, 54.1%). Of the 109 interviewees, 83 (76.1%) reported working in research centers (as researchers or sub-researchers). Surprisingly, 31.2% of doctors recognized that they invite less than 1% of their patients to participate in clinical trials, although 98 (89.9%) consider patient participation in clinical trials to be extremely relevant. The main barriers to conducting research in the country were the low number of available trials (48.2%) and the lack of qualified human resources to equip research sites (22.9%). Other barriers reported were the lengthy regulatory approval process (42.2%), followed by patients' lack of knowledge of clinical research, resulting in low recruitment rates (24.1%). Of the 26 (23.8%) interviewees who do not work with research, 25 (96.1%) reported interest in getting involved, 31.8% had already tried to participate in research, and 62.4% reported limited knowledge of clinical trial procedures.
Conclusion: These results suggest a clear need for greater involvement of physicians in clinical research activities in Brazil. Patient education strategies should improve low recruitment rates and, secondarily, increase the number of trials proposed in the country.
Authors:
Heloisa Resende, Taiane Francieli Rebelatto, Gustavo Werutsky, Gustavo Cartaxo de Lima Gössling, Vinícius Aguiar, Guilherme Lopes, Biazi Assis, Lilian Martins Arruda, Carlos H. Barrios
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
During the official ceremony of the 2023 SBOC Congress, on November 17, the FIP-SBOC Award was awarded to notable projects that stood out significantly in the fight against cancer in Brazil. Among the winners, the Acceleration Project stood out as a promising initiative to accelerate the diagnosis and treatment of breast cancer in the country.
The Acceleration Project, led by Dr. José Bines and with the Cura Project Institute as co-director, received recognition and donation of R$ 150,000, for its Phase 2, from the SBOC Research Incentive Fund (FIP). This Fund aims to support the development of Brazilian oncology research studies and initiatives focusing on reducing disparities and seeking equitable access to treatments.
Acceleration Project
Starting in 2022, in its initial phase, the Acceleration Project brought together a fundamental partnership with the health team of the Zilda Arns Family Clinic, in Complexo do Alemão. During this period, educational activities were carried out on breast cancer, in addition to the establishment of the registry and the trajectory of patients resident in that location.
Phase 2 Acceleration Project
General Objective: To decrease breast cancer mortality by reducing its presentation in advanced advances (III and IV).
Main Objective: Reduce the time interval between suspicion and treatment of breast cancer, currently from 6 to 8 months, to less than 3 months.
In the Brazilian context, the breast lesion biopsy and the histopathological report represent bottlenecks in the timely diagnosis and initiation of breast cancer treatment. The innovative proposal of the Acceleration Project aims to reduce these obstacles, improving the outcomes of this disease that affects so many lives.
The continuity of the project focuses on training Primary Health Care professionals to perform ultrasound and biopsy of suspected palpable breast lesions at the point of care. The speed and accuracy in obtaining the histopathological report are key elements to accelerate the diagnosis, delaying the time until the start of treatment and, consequently, reducing mortality from breast cancer.
The project strategy is to shift the focus from the current emphasis on mammographic screening to the implementation of an early diagnosis, through an approach based on adequate resources. The objective is to prevent a significant number of deaths from breast cancer, changing the current reality.
SBOC Research Incentive Fund (FIP) Award
The recognition and award of the Acceleration Project, in the SBOC Research Incentive Fund (FIP), represent a significant milestone in the oncology research scene in Brazil and in the continuous effort to address breast cancer in Brazil, promoting innovation and advancement in the approach to this complex disease. The importance of the Cura Project Institute as co-director of this project stands out as an important initial supporter for the success and positive impact of this initiative.
The FIP-SBOC Award highlights not only the quality of the research, but also the direct impact on patients' lives, signaling a more hopeful future in the Brazilian oncology scene and the role of the Cura Project Institute with the project, highlights its commitment to promoting oncological research in Brazil, and the partnership between Dr. José Bines and the Cura Project Institute highlights the important collaboration between professionals and institutions, engaged in advances in cancer treatment.
To make a donation and learn more about our projects, visit our Donation tab, follow our Social Networks @projetocura (Instagram, Facebook and LinkedIn) or contact us at eventos@projetocura.org.
Follow CURA on social media
© 2023 Cura Project Institute. All rights reserved.
.png)
%2009.03.42_25ab39ef.jpg)
